Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | March 29, 2018 | April 02, 2018 |
| WELLS FARGO & COMPANY/MNWFC · Entity 2824 | Director | April 01, 2013 | April 02, 2013 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date March 29, 2018 · Filed April 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 27,375.7941 |
Reported balance
After 2018-03-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-29 · Grant · Acquired 205.4266 · Balance 27,375.7941 F1: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of Gilead common stock.
F2: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate.
F3: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.
WELLS FARGO & COMPANY/MN
Report date April 01, 2013 · Filed April 02, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 61,962.9483 |
Reported balance
After 2013-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2013-04-01 · Grant · Acquired 1,651.7736 · Balance 61,962.9483 F2: Conversion price is 1-for-1 F3: Deferred compensation shares payable in installments depending upon director's election. |
| Common Stock, $1 2/3 Par ValueSEC Table I · non-derivative | Direct | 1,122.938 |
Reported balance
Holding disclosure · report date 2013-04-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,122.938 F1: Includes 7.866 shares acquired through Wells Fargo & Company's dividend reinvestment plan on 3/1/2013. |
| Common Stock, $1 2/3 Par ValueSEC Table I · non-derivative | IndirectThrough Family Trust | 1,000 |
Reported balance
Holding disclosure · report date 2013-04-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 7.866 shares acquired through Wells Fargo & Company's dividend reinvestment plan on 3/1/2013.
F2: Conversion price is 1-for-1
F3: Deferred compensation shares payable in installments depending upon director's election.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 30, 2013 Filed Sep 4, 2013 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative | 21,720 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001179110-13-013834 · edgar.xml · derivative · entry 5 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 21,720 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from the date of grant. Read SEC document |
| August 30, 2013 Filed Sep 4, 2013 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 4,816 | $61.02 | $293,860.28 |
DisclosureSEC source: 0001179110-13-013834 · edgar.xml · nonDerivative · entry 4 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 0 F5 · price: Sale prices reported for the transactions reported here range from $60.97 to $61.12. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 30, 2013 Filed Sep 4, 2013 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 146,904 | $60.40 | $8,872,722.48 |
DisclosureSEC source: 0001179110-13-013834 · edgar.xml · nonDerivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 4,816 F4 · price: Sale prices reported for the transactions reported here range from $59.97 to $60.96. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 30, 2013 Filed Sep 4, 2013 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 21,720 | $19.63 | $426,363.60 |
DisclosureSEC source: 0001179110-13-013834 · edgar.xml · nonDerivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 151,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2013 Filed Sep 4, 2013 23:09 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 130,000 | $20.71 | $2,691,650.00 |
DisclosureSEC source: 0001179110-13-013834 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 22:00 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Shares · Derivative | 784 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-011560 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,273 Underlying: Common Stock · 784 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| June 28, 2013 Filed Aug 14, 2013 18:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftNon-Qualified Stock Options (right to buy) · Derivative | 130,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001179110-13-013122 · edgar.xml · derivative · entry 4 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2017-05-09 F1 · kind: Transferred to a trust where the Reporting Person is the trustor. F3 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| June 28, 2013 Filed Aug 14, 2013 18:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftNon-Qualified Stock Options (right to buy) · Derivative | 21,720 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001179110-13-013122 · edgar.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 21,720 Underlying: Common Stock · 21,720 shares Expires 2020-05-11 F1 · kind: Transferred to a trust where the Reporting Person is the trustor. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from the date of grant. Read SEC document |
| June 28, 2013 Filed Aug 14, 2013 18:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftNon-Qualified Stock Options (right to buy) · Derivative | 130,000 | $0.00 Strike: $20.71 | $0.00 |
DisclosureSEC source: 0001179110-13-013122 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 130,000 shares Expires 2017-05-09 F1 · kind: Transferred to a trust where the Reporting Person is the trustor. F3 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| June 28, 2013 Filed Aug 14, 2013 18:39 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftNon-Qualified Stock Options (right to buy) · Derivative | 21,720 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001179110-13-013122 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,720 shares Expires 2020-05-11 F1 · kind: Transferred to a trust where the Reporting Person is the trustor. F2 · derivative.exercise_date: Options vest quarterly over a period of one year from the date of grant. Read SEC document |
| May 08, 2013 Filed May 10, 2013 22:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 2,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-008231 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,979 Underlying: Common Stock · 2,863 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 08, 2013 Filed May 10, 2013 22:16 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 8,442 | $0.00 Strike: $52.38 | $0.00 |
DisclosureSEC source: 0001179110-13-008231 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,442 Underlying: Common Stock · 8,442 shares Expires 2023-05-08 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| April 01, 2013 Filed Apr 2, 2013 20:01 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,651.7736 | $36.93 | $61,000.00 |
DisclosureSEC source: 0001127602-13-012868 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,962.9483 Underlying: Common Stock, $1 2/3 Par Value · 1,651.7736 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| March 01, 2013 Filed Mar 7, 2013 17:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionPhantom Stock · Derivative | 167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-004463 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,489 Underlying: Common Stock · 167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F3 · shares: An aggregate of 167.164 shares were reported in Table II when reporting person acquired the phantom shares. The fractional share of 0.164 was paid out in cash in connection with the conversion into shares of common stock. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| March 01, 2013 Filed Mar 7, 2013 17:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-004463 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock, except fractional shares are paid in cash. Read SEC document |
| January 02, 2013 Filed Jan 3, 2013 17:08 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,119.0755 | $34.18 | $38,250.00 |
DisclosureSEC source: 0001127602-13-000495 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,888.1165 Underlying: Common Stock, $1 2/3 Par Value · 1,119.0755 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| November 30, 2012 Filed Dec 4, 2012 21:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 65,000 | $0.00 Strike: $28.68 | $0.00 |
DisclosureSEC source: 0001179110-12-016872 · edgar.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2016-05-10 F1 · derivative.exercise_date: Options are 100% vested on the date of grant. Read SEC document |
| November 30, 2012 Filed Dec 4, 2012 21:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 65,000 | $74.96 | $4,872,549.50 |
DisclosureSEC source: 0001179110-12-016872 · edgar.xml · nonDerivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,309 F2 · price: Sale prices reported for the transactions reported here range from $74.78 to $75.12. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 30, 2012 Filed Dec 4, 2012 21:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 65,000 | $28.68 | $1,863,875.00 |
DisclosureSEC source: 0001179110-12-016872 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2012 Filed Oct 2, 2012 20:12 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,044.6686 | $34.70 | $36,250.00 |
DisclosureSEC source: 0001127602-12-027844 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,379.9592 Underlying: Common Stock, $1 2/3 Par Value · 1,044.6686 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| July 02, 2012 Filed Jul 3, 2012 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Shares · Derivative | 784 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-011187 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,329 Underlying: Common Stock · 784 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| July 01, 2012 Filed Jul 3, 2012 15:09 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,203.6483 | $33.44 | $40,250.00 |
DisclosureSEC source: 0001127602-12-021285 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,967.0055 Underlying: Common Stock, $1 2/3 Par Value · 1,203.6483 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| May 10, 2012 Filed May 15, 2012 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 2,926 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008422 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,558 Underlying: Common Stock · 2,926 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 10, 2013, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 10, 2013, at the end of the first year of service. Read SEC document |
| May 10, 2012 Filed May 15, 2012 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 8,161 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001179110-12-008422 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,161 Underlying: Common Stock · 8,161 shares Expires 2022-05-10 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 10, 2013. Read SEC document |
| April 24, 2012 Filed Apr 25, 2012 16:52 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 4,536 | $33.07 | $150,005.52 |
DisclosureSEC source: 0001127602-12-014617 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,359.5409 Underlying: Common Stock, $1 2/3 Par Value · 4,536 shares Expires not disclosed F1 · derivative.exercise_price: Conversion price is 1-for-1 F2 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F2 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| April 02, 2012 Filed Apr 3, 2012 16:24 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,178.969 | $34.14 | $40,250.00 |
DisclosureSEC source: 0001127602-12-012686 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,823.5409 Underlying: Common Stock, $1 2/3 Par Value · 1,178.969 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| March 01, 2012 Filed Mar 6, 2012 01:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionPhantom Stock · Derivative | 83 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-004355 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,545 Underlying: Common Stock · 83 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock were fully vested and, at the election of the reporting person, became payable in common stock on the specified date. F2 · derivative.expiration_date: The shares of phantom stock were fully vested and, at the election of the reporting person, became payable in common stock on the specified date. Read SEC document |
| March 01, 2012 Filed Mar 6, 2012 01:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 83 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-004355 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. Read SEC document |
| February 08, 2012 Filed Feb 10, 2012 20:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $19.44 | $0.00 |
DisclosureSEC source: 0001179110-12-002309 · edgar.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2015-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested in full on May 10, 2005. Read SEC document |
| February 08, 2012 Filed Feb 10, 2012 20:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 65,000 | $54.29 | $3,528,765.50 |
DisclosureSEC source: 0001179110-12-002309 · edgar.xml · nonDerivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,226 F2 · price: Sale prices reported for the transactions reported here range from $54.22 to $54.33. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 08, 2012 Filed Feb 10, 2012 20:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 65,000 | $19.44 | $1,263,275.00 |
DisclosureSEC source: 0001179110-12-002309 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2012 Filed Jan 4, 2012 19:00 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,387.881 | $27.56 | $38,250.00 |
DisclosureSEC source: 0001127602-12-000470 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,310.4718 Underlying: Common Stock, $1 2/3 Par Value · 1,387.881 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| September 30, 2011 Filed Oct 3, 2011 21:27 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,585.8209 | $24.12 | $38,250.00 |
DisclosureSEC source: 0001127602-11-026407 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,701.2393 Underlying: Common Stock, $1 2/3 Par Value · 1,585.8209 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| July 01, 2011 Filed Jul 6, 2011 22:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Shares · Derivative | 1,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-010710 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930 Underlying: Common Stock · 1,930 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| July 01, 2011 Filed Jul 5, 2011 18:00 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,576.9779 | $28.06 | $44,250.00 |
DisclosureSEC source: 0001127602-11-020500 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,904.3639 Underlying: Common Stock, $1 2/3 Par Value · 1,576.9779 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| May 12, 2011 Filed May 14, 2011 01:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007990 · edgar.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,632 Underlying: Common Stock · 3,632 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 12, 2012, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 12, 2012, at the end of the first year of service. Read SEC document |
| May 12, 2011 Filed May 14, 2011 01:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 10,141 | $0.00 Strike: $41.29 | $0.00 |
DisclosureSEC source: 0001179110-11-007990 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,141 Underlying: Common Stock · 10,141 shares Expires 2021-05-12 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 12, 2012. Read SEC document |
| May 11, 2011 Filed May 14, 2011 01:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007990 · edgar.xml · derivative · entry 4 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 11, 2011, at the end of the first year of service. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 11, 2011, at the end of the first year of service. Read SEC document |
| May 11, 2011 Filed May 14, 2011 01:17 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007990 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 03, 2011 Filed May 4, 2011 16:32 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 4,745 | $29.51 | $140,024.95 |
DisclosureSEC source: 0001127602-11-015014 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,140.6789 Underlying: Common Stock, $1 2/3 Par Value · 4,745 shares Expires not disclosed F1 · derivative.exercise_price: Conversion price is 1-for-1 F2 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F2 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| April 01, 2011 Filed Apr 4, 2011 20:43 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,332.8076 | $31.70 | $42,250.00 |
DisclosureSEC source: 0001127602-11-012068 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,395.6789 Underlying: Common Stock, $1 2/3 Par Value · 1,332.8076 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| January 03, 2011 Filed Jan 4, 2011 16:30 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,169.7322 | $30.99 | $36,250.00 |
DisclosureSEC source: 0001127602-11-000372 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,920.783 Underlying: Common Stock, $1 2/3 Par Value · 1,169.7322 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| October 01, 2010 Filed Oct 4, 2010 18:18 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,442.499 | $25.13 | $36,250.00 |
DisclosureSEC source: 0001127602-10-024462 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,683.6424 Underlying: Common Stock, $1 2/3 Par Value · 1,442.499 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| July 01, 2010 Filed Jul 6, 2010 18:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Shares · Derivative | 2,372.58 | $0.00 Strike: $34.14 | $0.00 |
DisclosureSEC source: 0001179110-10-011407 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,372.58 Underlying: Common Stock · 2,372.58 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| July 01, 2010 Filed Jul 2, 2010 17:33 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 1,494.1406 | $25.60 | $38,250.00 |
DisclosureSEC source: 0001127602-10-018487 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,166.48 Underlying: Common Stock, $1 2/3 Par Value · 1,494.1406 shares Expires not disclosed F2 · derivative.exercise_price: Conversion price is 1-for-1 F3 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F3 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| May 11, 2010 Filed May 13, 2010 23:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-008588 · edgar.xml · derivative · entry 2 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,820 Underlying: Common Stock · 3,820 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 11, 2011, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 11, 2011, at the end of the first year of service. Read SEC document |
| May 11, 2010 Filed May 13, 2010 23:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 10,860 | $0.00 Strike: $39.26 | $0.00 |
DisclosureSEC source: 0001179110-10-008588 · edgar.xml · derivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,860 Underlying: Common Stock · 10,860 shares Expires 2020-05-11 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 11, 2011. Read SEC document |
| May 06, 2010 Filed May 10, 2010 21:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 3,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-008259 · edgar.xml · nonDerivative · entry 1 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,406 F1 · shares: Issuance of common stock upon vesting of certain restricted share units on May 6, 2010. Read SEC document |
| April 27, 2010 Filed Apr 28, 2010 21:34 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantPhantom Stock Units · Derivative | 2,207 | $31.72 | $70,006.04 |
DisclosureSEC source: 0001127602-10-012322 · form4.xml · derivative · entry 4 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,613.7584 Underlying: Common Stock, $1 2/3 Par Value · 2,207 shares Expires not disclosed F1 · derivative.exercise_price: Conversion price is 1-for-1 F2 · derivative.exercise_date: Deferred compensation shares payable in installments depending upon director's election. F2 · derivative.expiration_date: Deferred compensation shares payable in installments depending upon director's election. Read SEC document |
| April 27, 2010 Filed Apr 28, 2010 21:34 UTC | WELLS FARGO & COMPANY/MN WFC · Entity 2824 | GrantDirector Stock Purchase Option · Derivative | 7,570 | $0.00 Strike: $31.72 | $0.00 |
DisclosureSEC source: 0001127602-10-012322 · form4.xml · derivative · entry 3 MOORE NICHOLAS G · CIK 0001216923 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,570 Underlying: Common Stock, $1 2/3 Par Value · 7,570 shares Expires 2020-04-27 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.